364 related articles for article (PubMed ID: 26434665)
1. Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus.
Ilag LL; Deeg MA; Costigan T; Hollander P; Blevins TC; Edelman SV; Konrad RJ; Ortmann RA; Pollom RK; Huster WJ; Zielonka JS; Prince MJ
Diabetes Obes Metab; 2016 Feb; 18(2):159-68. PubMed ID: 26434665
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine.
Hadjiyianni I; Dahl D; Lacaya LB; Pollom RK; Chang CL; Ilag LL
Diabetes Obes Metab; 2016 Apr; 18(4):425-9. PubMed ID: 26749289
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus.
Wang W; Song X; Lou Y; Du L; Zhu D; Zhou Z
Diabetes Obes Metab; 2022 Jun; 24(6):1094-1104. PubMed ID: 35187770
[TBL] [Abstract][Full Text] [Related]
4. Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study).
Rosenstock J; Hollander P; Bhargava A; Ilag LL; Pollom RK; Zielonka JS; Huster WJ; Prince MJ
Diabetes Obes Metab; 2015 Aug; 17(8):734-41. PubMed ID: 25931141
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study.
Blevins TC; Dahl D; Rosenstock J; Ilag LL; Huster WJ; Zielonka JS; Pollom RK; Prince MJ
Diabetes Obes Metab; 2015 Aug; 17(8):726-33. PubMed ID: 25974640
[TBL] [Abstract][Full Text] [Related]
6. Comparable efficacy and safety between LY2963016 insulin glargine and insulin glargine (Lantus®) in Chinese patients with type 1 diabetes: A phase III, randomized, controlled trial.
Yan X; Jiang S; Lou Y; Zhou Z
Diabetes Obes Metab; 2021 Oct; 23(10):2226-2233. PubMed ID: 34121308
[TBL] [Abstract][Full Text] [Related]
7. Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus.
Linnebjerg H; Lam EC; Zhang X; Seger ME; Coutant D; Chua L; Kapitza C; Heise T
Diabetes Obes Metab; 2017 Jan; 19(1):33-39. PubMed ID: 27484286
[TBL] [Abstract][Full Text] [Related]
8. Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies.
Sun B; Sengupta N; Rao A; Donnelly C; Waichale V; Roy AS; Ramaswamy S; Pathak D; Bowsher RR; Raiter Y; Aubonnet P; Barve A
BMC Endocr Disord; 2021 Jun; 21(1):129. PubMed ID: 34174848
[TBL] [Abstract][Full Text] [Related]
9. LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes.
Lamb YN; Syed YY
BioDrugs; 2018 Feb; 32(1):91-98. PubMed ID: 29368288
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study.
Christofides EA; Puente O; Norwood P; Denham D; Maheshwari H; Lillestol M; Hart T; Nakhle S; Chadha A; Fitz-Patrick D; Sugimoto D; Soufer J; Young D; Warren M; Huffman D; Reed J; Bays H; Arora S; Rizzardi B; Tidman R; Rendell M; Johnson KA
Diabetes Obes Metab; 2024 Jun; 26(6):2412-2421. PubMed ID: 38558508
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 1 Diabetes Also Using Insulin Glargine-SORELLA 1 Study.
Garg SK; Wernicke-Panten K; Rojeski M; Pierre S; Kirchhein Y; Jedynasty K
Diabetes Technol Ther; 2017 Sep; 19(9):516-526. PubMed ID: 28722480
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type 1 Diabetes Previously Treated with Insulin Glargine (Lantus
Yan X; Feng C; Lou Y; Zhou Z
Diabetes Ther; 2022 Jun; 13(6):1161-1174. PubMed ID: 35471721
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of LY2963016 insulin glargine versus insulin glargine (Lantus) in Chinese adults with type 2 diabetes: A phase III, randomized, open-label, controlled trial.
Feng W; Chen W; Jiang S; Du L; Zhu D
Diabetes Obes Metab; 2021 Aug; 23(8):1786-1794. PubMed ID: 33783964
[TBL] [Abstract][Full Text] [Related]
14. Single-dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK-1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects.
Crutchlow MF; Palcza JS; Mostoller KM; Mahon CD; Barbour AM; Marcos MC; Xu Y; Watkins E; Morrow L; Hompesch M
Diabetes Obes Metab; 2018 Feb; 20(2):400-408. PubMed ID: 28817223
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of MYL-1501D vs insulin glargine in patients with type 1 diabetes after 52 weeks: Results of the INSTRIDE 1 phase III study.
Blevins TC; Barve A; Sun B; Ankersen M
Diabetes Obes Metab; 2018 Aug; 20(8):1944-1950. PubMed ID: 29656504
[TBL] [Abstract][Full Text] [Related]
16. LY2963016 Insulin Glargine and Insulin Glargine (Lantus) Produce Comparable Pharmacokinetics and Pharmacodynamics at Two Dose Levels.
Zhang X; Lam ECQ; Seger ME; Coutant D; Chua L; Tan LH; Soon D; Linnebjerg H
Clin Pharmacol Drug Dev; 2017 Nov; 6(6):556-563. PubMed ID: 28940840
[TBL] [Abstract][Full Text] [Related]
17. Lilly Insulin Glargine Versus Lantus
Mohan V; Ahn KJ; Cho YM; Sahay RK; Huang CN; Kalra S; Chadha M; Bhattacharya I; Kim SY; Spaepen E
Clin Drug Investig; 2019 Aug; 39(8):745-756. PubMed ID: 31119716
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of two insulin glargine formulations: biosimilar vs. reference product].
Mönnig E; Schloot N; Hohberg C; Wiesner T; Heinemann L
MMW Fortschr Med; 2016 Aug; 158 Suppl 5():19-27. PubMed ID: 27565486
[TBL] [Abstract][Full Text] [Related]
19. [LY2963016 insulin glargine: The first biosimilar insulin approved in the European Union].
Altman JJ; Chevalier N; Delemer B; Travert F; Benabbad I
Presse Med; 2018 Oct; 47(10):854-866. PubMed ID: 30262205
[TBL] [Abstract][Full Text] [Related]
20. Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus
Ilag LL; Costigan TM; Deeg MA; Pollom RK; Chang CL; Konrad RJ; Prince MJ
Diabetes Ther; 2017 Jun; 8(3):545-554. PubMed ID: 28361463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
